Patent ID: 8357393

Claim:
A non-occlusive transdermal pharmaceutical composition suitable for transdermal administration and capable of transdermal delivery of a physiologically active agent comprising: (a) from 0.1% to 10% by weight of one or more active agents selected from the group consisting of fentanyl, buspirone and granisetron; (b) from 0.1% to 10% by weight of one or more dermal penetration enhancers selected from the group consisting of octyl salicylate and Padimate O; and (c) from 85% to 99.8% by weight of a volatile solvent selected from the group consisting of ethanol, isopropanol, and mixtures thereof; wherein the combination of physiologically active agent(s) and dermal penetration enhancer(s) is such that the composition, upon application and evaporation of the solvent at physiological temperatures, forms an amorphous deposit comprising an amorphous phase, containing the dermal penetration enhancer(s) and physiologically active agent(s), which amorphous phase does not display crystallinity, when determined in vitro by Brightfield microscopy after evaporation of the solvent at 32° C. and ambient relative humidity for 24 hours.